Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years And early ctDNA reductions correlated with survival Oct 21, 2023
Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer But label update planned after potential harm observed in PD-L1-negative subgroup Oct 20, 2023
Hand Cooling, Compression Both Effective for Nerve Pain in Breast Cancer But access, cost, and tolerability may favor the latter option, said researcher Sep 14, 2022
Potential Practice-Changer for Refractory Metastatic Colon Cancer Significant survival gain with fruquintinib in patients with heavily pretreated disease Sep 14, 2022
Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancer "Encouraging activity" with enfortumab vedotin-pembrolizumab in patients with high unmet need Sep 14, 2022
Long-Term ADT With Radiation Helps Prevent Post-Prostatectomy Metastases However, no benefit seen with short-term hormone therapy versus radiotherapy alone Sep 13, 2022
Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma Large increase in event-free survival with neoadjuvant plus adjuvant versus only adjuvant therapy Sep 13, 2022
KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLC "New second-line standard" in KRAS G12C-mutant disease, says study investigator Sep 13, 2022
Triplet in First-Line Kidney Cancer Thwarts Disease Progression Randomized study shows "clinically meaningful" PFS improvement over dual immunotherapy alone Sep 13, 2022
Survival Bump in Unfit NSCLC With First-Line Immunotherapy Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets Sep 12, 2022
Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma Pathologic complete responses seen in 63% of patients in phase II data Sep 12, 2022
Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinoma Studies appear to contradict benefit previously shown with pembrolizumab in this setting Sep 12, 2022
Combination Therapy Shows Promise for NSCLC That Progresses on Osimertinib About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists Sep 12, 2022
'Striking' Colon Cancer Data Spur Mid-Presentation Ovation at ESMO Preoperative immunotherapy combo in dMMR disease yields major pathologic response in 95% Sep 12, 2022
Tumor Infiltrating Lymphocytes Reemerge as Potential Melanoma Option More than 50% increase in 6-month PFS versus ipilimumab after progression on first-line anti-PD-1 Sep 12, 2022
Add-On Pembrolizumab Misses in Locally Advanced Head and Neck Cancer Post hoc data point to possible benefit in patients with higher PD-L1 levels Sep 11, 2022
Locking Down a Link Between Pollution and EGFR-Mutated Lung NSCLC Study also shed lights on what may lead to lung cancer in never smokers Sep 11, 2022
'Potential New Standard' for Progressing Desmoid Tumors Risk of disease progression or death reduced by 71% with oral gamma secretase inhibitor Sep 10, 2022
Targeted Combo Flops as First-Line Treatment in Advanced Breast Cancer No clinical benefit boost with anti-CD73 oleclumab added to durvalumab and chemo Sep 10, 2022
Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials Results from SOLO-1 and PAOLA-1 show "clinically meaningful" long-term results with olaparib Sep 09, 2022
Worse OS With Rucaparib First in Trial of Recurrent, BRCA+ Ovarian Cancer A closer look at why PARP inhibitor's third-line indication was withdrawn Sep 09, 2022
Antibody-Drug Conjugate Prolongs Survival in Metastatic Breast Cancer Positive outcome with sacituzumab govitecan leads to questions about ADC sequencing Sep 09, 2022
Checkpoint Inhibitors Whiff in Head and Neck Cancer Trials Avelumab, nivolumab-ipilimumab, pembrolizumab miss endpoints in separate studies Sep 23, 2021
Survey Says: Support Is Lacking for Cancer's Lingering Effects Survivors report dissatisfaction with long-term support Sep 22, 2021
Angiogenesis Inhibitor Slows Extrapancreatic Neuroendocrine Tumors Almost 7-month increase in median PFS with addition of axitinib to endocrine therapy Sep 21, 2021
Transarterial Radioembolization Slows Progression of CRC With Liver Mets Small increase in median PFS when combined with second-line chemotherapy Sep 21, 2021
Androgen-Targeting Combos Show Promise in Prostate Cancer Trials extend survival in hormone-sensitive disease Sep 21, 2021
Bifunctional Protein Shows Promise in HPV-Related Cancers Objective responses in 28% of pretreated patients, durable in most cases Sep 20, 2021
Sunitinib Effective in Very Rare Neuroendocrine Tumor The TKI boosted PFS in patients with malignant pheochromocytoma and paraganglioma Sep 20, 2021
Chemo Plus Keytruda Boosts Overall Survival in Advanced TNBC KEYNOTE-355 regimen offers "transformative treatment" in PD-L1-positive disease, expert says Sep 20, 2021
ADC Makes a Case for Role in Metastatic HER2-Positive Breast Cancer Improved progression-free survival in previously treated disease with trastuzumab duocarmazine Sep 20, 2021
Combo Treatment Extends Survival in HR+HER2- Advanced Breast Cancer MONALEESA-2's "big message": 12.5-month boost in median OS with ribociclib-aromatase inhibitor Sep 19, 2021
Another Possible Option for HER2-Mutated Non-Small Cell Lung Cancer More than half of patients responded to antibody-drug conjugate targeting HER2 Sep 19, 2021
Adjuvant Pembrolizumab Boosts Recurrence-Free Survival in High-Risk Melanoma Also, fewer cases of distant recurrences in KEYNOTE-716 trial Sep 19, 2021
Practice-Changing Study in Advanced Cervical Cancer Improved PFS, OS with pembrolizumab and chemo with or without bevacizumab Sep 18, 2021
Trastuzumab Deruxtecan: New Standard of Care in Pretreated, Advanced Breast Cancer? DESTINY-Breast03 turns in "absolutely startling" PFS in HER2-positive metastatic disease Sep 18, 2021
Extended Letrozole Reduced Recurrence Risk in Postmenopausal Breast Cancer 5 years of the aromatase inhibitor improved disease-free survival vs 2-3 years Sep 17, 2021
Rechallenge With PARP Inhibitor Slows Relapsed Ovarian Cancer Benefits platinum-sensitive disease irrespective of BRCA, homologous repair status, study showed Sep 17, 2021
Cancer Patients, COVID-19, and Long-Term Effects Preventing COVID sequelae can minimize disruption of cancer care, European study finds Sep 09, 2021
Keytruda Before, After Surgery Improves Outcome in TNBC Results from KEYNOTE-522 show "practice-changing" impact on EFS Jul 15, 2021